British Journal of Haematology

• 

  Publication Venue For

  • Trends in primary central nervous system lymphoma incidence and survival in the U.S..  174:417-424. 2016
  • Coagulation activation in sickle cell trait: an exploratory study.  171:638-646. 2015
  • Corrigendum.  160:723-723. 2013
  • Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria.  162:62-73. 2013
  • Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research..  137:479-485. 2007
  • Aplastic anaemia as an autoimmune complication of thymoma..  137:272. 2007
  • Genetic polymorphisms associated with priapism in sickle cell disease..  137:262-267. 2007
  • Effect of myeloablative bone marrow transplantation on growth in children with sickle cell anaemia: results of the multicenter study of haematopoietic cell transplantation for sickle cell anaemia..  136:673-676. 2007
  • Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia..  134:314-319. 2006
  • The effect of aprotinin on activated protein C-mediated downregulation of endogenous thrombin generation..  134:77-82. 2006
  • High dose factor VIIa improves clot structure and stability in a model of haemophilia B..  131:645-655. 2005
  • Genotype-phenotype correlation in MYH9-related thrombocytopenia..  130:620-627. 2005
  • Co-operative signalling mechanisms required for erythroid precursor expansion in response to erythropoietin and stem cell factor..  130:121-129. 2005
  • Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia..  128:853-862. 2005
  • Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study..  128:49-58. 2005
  • Mobilization of dendritic cells in cancer patients treated with granulocyte colony-stimulating factor and chemotherapy..  119:204-211. 2002
  • Change in serum procalcitonin (deltaPCT) predicts the clinical outcome of children admitted with febrile neutropenia..  118:1197-1198. 2002
  • High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system..  114:114-120. 2001
  • Stem cell transplantation for the treatment of Fanconi anaemia using a fludarabine-based cytoreductive regimen and T-cell-depleted related HLA-mismatched peripheral blood stem cell grafts..  111:1153-1157. 2000
  • Herpes virus infections occur frequently following treatment with fludarabine: results of a prospective natural history study..  105:445-447. 1999
  • Wintrobe's Clinical Haematology, 10th edn. . Edited by G. R. Lee, J. Foerster, J. Lukons, F. Paraskevar, J. P. Greer and G. M. Rodgers. Williams and Wilkins, Baltimore, 1999. Pp. 2764. f120..  105:572-572. 1999
  • Monitoring oral anticoagulant therapy in patients with lupus anticoagulants..  101:390-392. 1998
  • Platelet activity of high-dose factor VIIa is independent of tissue factor..  99:542-547. 1997
  • Acute lymphoblastic leukaemia in childhood: cell proliferation without rest..  96:366-368. 1997
  • Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia..  93:59-67. 1996
  • Allogeneic marrow transplantation for aplastic anaemia associated with dyskeratosis congenita..  92:758-765. 1996
  • Marrow transplantation for Fanconi anaemia: conditioning with reduced doses of cyclophosphamide without radiation..  92:699-706. 1996
  • Resolution of Budd-Chiari syndrome following bone marrow transplantation for paroxysmal nocturnal haemoglobinuria..  92:707-710. 1996
  • PIG-A, DAF and proto-oncogene expression in paroxysmal nocturnal haemoglobinuria-associated acute myelogenous leukaemia blasts..  89:72-78. 1995
  • The role of CD45RO in antithymocyte globulin's stimulation of primitive haemopoietic cells..  88:643-646. 1994
  • Platelet procoagulant complex assembly in a tissue factor-initiated system..  88:364-371. 1994
  • Long-term survival and cure after marrow transplantation for congenital hypoplastic anaemia (Diamond-Blackfan syndrome)..  84:515-520. 1993
  • Expression of multidrug resistance gene mdr1 mRNA in a subset of normal bone marrow cells..  81:145-152. 1992
  • A pilot study of low-dose cyclosporin for graft-versus-host prophylaxis in marrow transplantation..  80:49-54. 1992
  • The erythrocytes in paroxysmal nocturnal haemoglobinuria of intermediate sensitivity to complement lysis..  79:99-107. 1991
  • Absence of phosphatidylinositol (PI)-linked proteins in a very early human multipotential haematopoietic marrow cell..  77:145-149. 1991
  • A past mutation at isoleucine 397 is now a common cause of moderate/mild haemophilia B..  75:212-216. 1990
  • Previous donor pregnancy as a risk factor for acute graft-versus-host disease in patients with aplastic anaemia treated by allogeneic marrow transplantation..  74:492-496. 1990
  • Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial..  72:567-572. 1989
  • Factors associated with graft rejection after HLA-identical marrow transplantation for aplastic anaemia..  55:573-585. 1983
  • CANDIDATES FOR NORMAL COUNTERPARTS OF SEZARY CELLS AND ATLL CELLS IN THE PERIPHERAL-BLOOD.  55:191-192. 1983
  • Kinetics of elimination of antithrombin III concentrate in heparinized patients..  48:617-625. 1981
  • Two biochemical markers in lymphocyte subpopulations..  34:631-638. 1976
  • The abnormal surface characteristics of the red blood cell membrane in congenital dyserythropoietic anaemia type II (HEMPAS)..  30:383-394. 1975
  • Experimental transfusion reactions in monkeys: haemolytic, coagulant and renal effects of transfused isoimmune IgG and IgM..  23:765-776. 1972
  • The effect of unilateral limb shielding on the haemopoietic response of the guinea-pig to gamma irradiation (150 r.)..  12:365-375. 1966
  • Etavopivat, an investigational, once-daily, selective pyruvate kinase-R activator, improves sickle red blood cell health and survival in patients with sickle cell disease: an analysis of exploratory studies in a phase 1 trial 2022
  • "Superiority of Pegcetacoplan Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria, Regardless of Prior Transfusion Requirement: Analysis at 16-weeks of PEGASUS Phase 3 Randomized Trial" 2021
  • Categorized hematologic response to pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria: post hoc analysis of data from a phase 3 randomized trial (PEGASUS) 2021
  • Effect of Pegcetacoplan on Quality of Life in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Pegasus Phase 3 Trial Comparing Pegcetacoplan to Eculizumab 2021
  • FT-4202, an allosteric activator of pyruvate kinase-R, demonstrates proof of mechanism and proof of concept after multiple daily doses in a phase 1 study of patients with sickle cell disease 2021
  • Preliminary gastrointestinal safety and tolerability of fedratinib from the phase IIIb FREEDOM trial in patients with intermediateor high-risk myelofibrosis previously treated with ruxolitinib 2021
  • Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria 2021
  • Venetoclax as Targeted Therapy for Relapsed/Refractory Multiple Myeloma 2018